Display options
Cite
Onady GM, Langdon LJ. Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocr Disord. 2006;6:4doi: 10.1186/1472-6823-6-4.
Onady, G. M., & Langdon, L. J. (2006). Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC endocrine disorders, 64. https://doi.org/10.1186/1472-6823-6-4
Onady, Gary M, and Langdon, Leora J. "Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study." BMC endocrine disorders vol. 6 (2006): 4. doi: https://doi.org/10.1186/1472-6823-6-4
Onady GM, Langdon LJ. Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocr Disord. 2006 Jun 21;6:4. doi: 10.1186/1472-6823-6-4. PMID: 16790062; PMCID: PMC1513574.
Copy Download .nbib Format: NLM
Share it on

BMC Endocr Disord. 2006 Jun 21;6:4. doi: 10.1186/1472-6823-6-4.

Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study.

BMC endocrine disorders

Gary M Onady, Leora J Langdon

Affiliations

  1. Wright State University School of Medicine, Medicine-Pediatrics Program, Suite 500 Elizabeth Place, Dayton, OH 45408, USA. [email protected]

PMID: 16790062 PMCID: PMC1513574 DOI: 10.1186/1472-6823-6-4

Abstract

BACKGROUND: Insulin is the recommend therapeutic agent of choice for the management of Cystic Fibrosis Related Diabetes (CFRD), despite only sub-optimal reductions in glycemic control and increased morbidity and mortality reported by centers using this agent. The newer insulin sensitizing agents demonstrated to have anti-inflammatory mechanisms may provide an alternative management option for CFRD.

METHODS: A prospective case based therapeutic comparison between insulin, sulfonylurea, metformin and thiazolidinedione was observed over one decade with 20 CFRD patients diagnosed using American Diabetes Association guideline standards. Patients entering the study elected treatment based on risk and benefit information provided for treatment options. Patients receiving organ transplant or requiring combination diabetic medications were excluded from the study.

RESULTS: No statistical advantage was achieved regarding overall glycemic control for oral agents over insulin. Additional outcome measures including changes in weight, liver function testing and FEV1 were not statistically significant.

CONCLUSION: Insulin alone may not be the only therapeutic option in managing CFRD. Oral hypoglycemic agents were equally effective in treating CFRD and may provide an alternative class of agents for patients reluctant in using insulin.

References

  1. J Am Diet Assoc. 1994 Jan;94(1):78-80 - PubMed
  2. Ir Med J. 1994 Mar-Apr;87(2):59-60 - PubMed
  3. Diabetes. 1994 Aug;43(8):1020-6 - PubMed
  4. Arch Intern Med. 1997 Sep 8;157(16):1802-17 - PubMed
  5. Endocrinol Metab Clin North Am. 1999 Dec;28(4):787-800, ix - PubMed
  6. Diabet Med. 2004 Jul;21(7):691-6 - PubMed
  7. Arch Intern Med. 2003 Nov 24;163(21):2594-602 - PubMed
  8. Biochem Pharmacol. 2003 Aug 15;66(4):663-77 - PubMed
  9. Br J Pharmacol. 2000 Jan;129(2):367-73 - PubMed
  10. J Pediatr. 1991 May;118(5):715-23 - PubMed
  11. Medicine (Baltimore). 1986 Nov;65(6):389-97 - PubMed
  12. Acta Paediatr. 2001 Aug;90(8):860-7 - PubMed
  13. J Pediatr Gastroenterol Nutr. 1994 Apr;18(3):375-8 - PubMed
  14. Eur J Intern Med. 2002 Oct;13(7):428 - PubMed
  15. BMJ. 1995 Sep 9;311(7006):655-9 - PubMed
  16. J Clin Endocrinol Metab. 1994 Jul;79(1):80-5 - PubMed
  17. Pediatrics. 1998 Mar;101(3 Pt 1):433-7 - PubMed

Publication Types